Loading...
>>Press Releases

Press Releases

3011, 2017

Exclusive License And Co-Development Agreement

By | November 30th, 2017|

Yuhan And Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. Enter Into Exclusive License And Co-Development Agreement For 3rd -Generation EGFR-Targeted Therapy In China

Load More Posts